FINANCE/FUNDING ARTICLES

• Paving The Way For Future Funding

  Growing a life sciences company will have continuous demands for funding. Wherever that money comes from, undertaking a commitment to PCAOB (Public Company Accounting Oversight Board) compliance will be valued by potential investors.

• The Drug-Delivery Company That Partnerships Built

  “Normally a company raises money, does their science, and hopes to get a deal. We were the inverse of that,” explains Joseph Payne, president and CEO of Arcturus Therapeutics.

• Is China’s Golden Era Ending?

  The value of China’s biotechs fell some 30 percent since the trade war began, and VC funding, while strong, slipped before that. Interest in China, however, remains strong.

• How Biopharma & Medtech CFOs Are Viewing U.S. Tax Reform

  Biopharma and medtech companies are expecting mostly positive results from the new Tax Cuts and Jobs Act (TCJA), according to research by The Deloitte Center for Health Solutions and Forbes Insights.

• How To Put A Price Tag On Emerging Therapies

  There’s no doubt that partnerships and M&As are key growth drivers in the biopharma industry.  But for collaborative relationships to occur, understanding the value of a company’s underlying assets is critical.

• Serendipity: When Funders Found A Company

  Foghorn Therapeutics is managing to sidestep some of the growing pains common to early companies, thanks to its genesis as a VC-founded company.

• When Should Tax Functions Be Brought In-House?

  At what stage of a biopharma’s growth does it makes sense to bring on an internal tax function? The answer, of course, varies significantly, but here are some factors to consider when making this important business decision.

• Recent Changes May Reshape Financial Reporting In The Life Sciences Industry

  Changes to the accounting standards that affect matters like revenue recognition, the definition of a business, and leases could significantly affect the accounting for certain transactions in the life sciences industry.

• Biopharma Startups Take Advantage Of Open IPO Window

  Biopharma startups are enjoying a window of opportunity for successful IPOs that opened in mid-2017. CEOs share their experiences of going public, what is fueling IPOs, and tips for others thinking about making this important next step.

• How Biotechs Can Avoid The Common Pitfalls Of Going Public

  Many private biotech companies have either initiated the process of going public or are at least contemplating it. But they should be aware of very significant pitfalls that lie in wait, regardless of how they approach the offering.